Sonesitatug vedotin
Sonesitatug vedotin is a Claudin 18.2 ADC in phase 3 for gastric cancer, licensed by AstraZeneca from KYM Biosciences.
Phase 1 ORR ~33% in CLDN18.2+ gastric cancer; CLARITY-Gastric01 phase 3 second-line ongoing. Competes with XNW27011 and other CLDN18.2 ADCs.
1.Antibody binds Claudin 18.2 on the tumour cell surface
- Route
- IV infusion
- Schedule
- 2.2 mg/kg every 3 weeks (phase 3 dose)
Source: clinicaltrials.gov/study/NCT06346392. Doses are for orientation; the current label governs.
Compare all products across the US, EU, UK, Japan, China and Australia →
- Feb 2023Filing / dealUS
AstraZeneca licenses global rights from KYM Biosciences source
| Adverse event |
|---|
| Nausea |
| Vomiting |
| Neutropenia |
| Decreased appetite |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational (CLARITY-Gastric01) | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Sonesitatug vedotin" OR ABSTRACT:"Sonesitatug vedotin" OR TITLE:"CMG901" OR ABSTRACT:"CMG901" OR TITLE:"AZD0901" OR ABSTRACT:"AZD0901") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sonesitatug vedotin, not a curated reading list.